Skip to main content

A higher standard of relief
for patients with gastroparesis

In a survey of 1,423 patients, only 4% were satisfied with available treatment options for gastroparesis.1 Gastric Electrical Stimulation (GES) with Enterra® Therapy sets a higher standard—designed to offer lasting relief from nausea and vomiting symptoms.

See if your patient is a candidate

In clinical studies, high patient satisfaction with gastroparesis symptom relief with Enterra Therapy was reported.

87%

patient satisfaction

at 1 year with
Enterra Therapy2

80%

Patient Satisfaction

at 5 years with
Enterra Therapy2

Recommending the right patients for Enterra Therapy

Enterra Therapy may be appropriate for patients who meet the following criteria: 

  • Have gastroparesis caused by diabetic or idiopathic origin
  • Have difficulty managing nausea and vomiting symptoms, despite having tried first-line therapies of diet modification and medications
  • Are 18-70 years of age
See if your patient is a candidate

Find an Enterra Therapy specialist

If you have a patient who may be a candidate for receiving Enterra Therapy, use this tool to find a trained implanter or GI specialist in your area.

Find a center
  1. Yu D, Ramsey FV, Norton WF, et al. The Burdens, Concerns, and Quality of Life of Patients with Gastroparesis. Dig Dis Sci.
    2017;62(4):879-893. doi:10.1007/s10620 017 4456-7.
  2. Cassidy DJ, Gerull W, Zike VM, Awad MM. Clinical outcomes of a large, prospective series of gastric electrical stimulation patients using a multidisciplinary protocol. Surg Endosc. 2024.
IMPORTANT SAFETY INFORMATION

Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.

HUMANITARIAN DEVICE

Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?